2021
DOI: 10.21203/rs.3.rs-1075411/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Translational Development of A Tumor Junction Opening Technology

Abstract: Our goal is to overcome treatment resistance in ovarian cancer patients, which occurs in most cases after an initial positive response to chemotherapy. A central resistance mechanism is the maintenance of desmoglein-2 (DSG2)-positive tight junctions between malignant cells, which prevents drug penetration into the tumor. We generated JO4, a recombinant protein that binds to DSG2, resulting in the transient opening of junctions in epithelial tumors. Here, we present studies on the clinical translation of JO4 in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 12 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?